Published in J Immunol Res on October 13, 2014
mTOR Inhibition Suppresses Posttransplant Alloantibody Production Through Direct Inhibition of Alloprimed B Cells and Sparing of CD8+ Antibody-Suppressing T cells. Transplantation (2016) 0.76
Unraveling the Role of Allo-Antibodies and Transplant Injury. Front Immunol (2016) 0.75
Impact of the Trough Level of Calcineurin Inhibitor on the Prevalence of Donor-Specific Human Leukocyte Antigen Antibodies During Long-Term Follow-Up After Pediatric Liver Transplantation: Antibody Strength and Complement-Binding Ability. Transplant Direct (2017) 0.75
Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med (2013) 6.31
Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med (2007) 5.31
Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant (2011) 4.06
Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant (2009) 3.43
Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant (2014) 3.43
Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol (2010) 2.66
Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation (2013) 2.55
Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant (2012) 2.46
De novo anti-HLA antibody after pandemic H1N1 and seasonal influenza immunization in kidney transplant recipients. Am J Transplant (2011) 2.28
De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant (2009) 2.24
Proinflammatory events are associated with significant increases in breadth and strength of HLA-specific antibody. Am J Transplant (2009) 2.22
Influence of test technique on sensitization status of patients on the kidney transplant waiting list. Am J Transplant (2013) 2.12
Humoral theory of transplantation. Am J Transplant (2003) 2.04
Complement-fixing donor-specific antibodies identified by a novel C1q assay are associated with allograft loss. Pediatr Transplant (2011) 1.91
Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int (1993) 1.80
Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant (2012) 1.78
Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant (2010) 1.56
Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation (2009) 1.47
Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation (2013) 1.33
The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. J Heart Lung Transplant (2013) 1.16
Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients. Transplantation (2010) 1.15
The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes. Transplantation (2013) 1.11
Posttransplant de novo donor-specific hla antibodies identify pediatric kidney recipients at risk for late antibody-mediated rejection. Am J Transplant (2012) 1.07
Posttransplant monitoring of de novo human leukocyte antigen donor-specific antibodies in kidney transplantation. Curr Opin Organ Transplant (2013) 1.03
Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant. Transplantation (2008) 1.00
HLA antibodies and the occurrence of early adverse events in the modern era of transplantation: a collaborative transplant study report. Transplantation (2009) 0.91
Serological characterization of antibodies eluted from chronically rejected human renal allografts. Transplantation (1981) 0.85
Living donor kidney transplantation in patients with donor-specific HLA antibodies enabled by anti-CD20 therapy and peritransplant apheresis. Atheroscler Suppl (2013) 0.81